Current clinical trials in Hodgkin's disease

被引:0
作者
Reuss, K [1 ]
Engert, A [1 ]
Tesch, H [1 ]
Diehl, V [1 ]
机构
[1] UNIV COLOGNE,MED KLIN 1,D-50924 COLOGNE,GERMANY
关键词
chemotherapy; clinical trials; current strategies; dose escalation; high-dose single agent chemotherapy; Hodgkin's disease; radiotherapy; time intensification; treatment;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the advent of modern polychemotherapy and radiation techniques, cure rates in Hodgkin's disease (HD) have improved substantially. This article summarises current concepts of treatment for early, intermediate and advanced stage HD. Current strategies focus on the balance between cure rate and toxicity. In early stages, cure rates approach 90% and new strategies mainly try to avoid toxicities. Possible approaches comprise the use of less CT or RT or leaving laparotomy. In advanced stages, polychemotherapy with 8 courses of either M(C)OPP or ABVD or M(C)OPP/ABVD is considered to be the treatment of choice, but unsatisfactory low complete remission rates, progression-free survival or freedom from treatment failure rates have to be improved. The role of additional radiotherapy after extensive chemotherapy in the treatment of advanced stages is uncertain. To achieve a better tumour control, new regimens have been developed. The Stanford group initiated the 12-week intensified hybrid protocol Stanford V. The German Hodgkin's Lymphoma Study Group (GHSG) introduced the BEACOPP protocol with time intensification and dose escalation of cyclophosphamide and etoposide. The Milan Cancer institute tries to improve treatment outcome using high doses of single agents. One problem to be addressed in ongoing and future trials is the identification of high-risk groups allowing an early stratification of patients into more aggressive but effective regimens. Risk-adapted therapy might allow further reduction of doses in patients with early-stage Hodgkin's disease.
引用
收藏
页码:109 / 113
页数:5
相关论文
共 27 条
[1]  
ANSELMO AP, 1992, HAEMATOLOGICA, V3, P217
[2]   BRIEF CHEMOTHERAPY, STANFORD-V, AND ADJUVANT RADIOTHERAPY FOR BULKY OR ADVANCED-STAGE HODGKINS-DISEASE - A PRELIMINARY-REPORT [J].
BARTLETT, NL ;
ROSENBERG, SA ;
HOPPE, RT ;
HANCOCK, SL ;
HORNING, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1080-1088
[3]   EXTENDED-FIELD RADIOTHERAPY IS SUPERIOR TO MOPP CHEMOTHERAPY FOR THE TREATMENT OF PATHOLOGICAL STAGE-I-IIA HODGKINS-DISEASE - 8-YEAR UPDATE OF AN ITALIAN PROSPECTIVE RANDOMIZED STUDY [J].
BITI, GP ;
CIMINO, G ;
CARTONI, C ;
MAGRINI, SM ;
ANSELMO, AP ;
ENRICI, RM ;
BELLESI, GP ;
BOSI, A ;
PAPA, G ;
GIANNARELLI, D ;
PONTICELLI, P ;
PAPI, MG ;
FERRINI, PLR ;
BIAGINI, C ;
MANDELLI, F .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :378-382
[4]   ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS [J].
BONADONNA, G ;
VALAGUSSA, P ;
SANTORO, A .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :739-746
[5]  
BONADONNA G, 1995, 3 INT S HODGK LYMPH
[6]  
CANELLOS GP, 1988, P AN M AM SOC CLIN, V7, P230
[7]   CLINICAL STAGING VERSUS LAPAROTOMY AND COMBINED-MODALITY WITH MOPP VERSUS ABVD IN EARLY-STAGE HODGKINS-DISEASE - THE H6 TWIN RANDOMIZED TRIALS FROM THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER LYMPHOMA COOPERATIVE GROUP [J].
CARDE, P ;
HAGENBEEK, A ;
HAYAT, M ;
MONCONDUIT, M ;
THOMAS, J ;
BURGERS, MJV ;
NOORDIJK, EM ;
TANGUY, A ;
MEERWALDT, JH ;
LEFUR, R ;
SOMERS, R ;
KLUINNELEMANS, HC ;
BUSSON, A ;
BREED, WP ;
BRON, D ;
HOLDRINET, A ;
RUTTEN, EHJM ;
MICHIELS, JJ ;
REGNIER, R ;
DEBUSSCHER, L ;
MUSELLA, R ;
FARGEOT, P ;
THYSS, A ;
CATTAN, A ;
RIGALHUGUET, F ;
ROTH, S ;
CAILLOU, B ;
DUPOUY, N ;
HENRYAMAR, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2258-2272
[8]  
DIEH V, UNPUB GHSG HDM TRIAL
[9]   COOPERATIVE TRIALS OF HODGKINS LYMPHOMA IN THE FEDERAL-REPUBLIC-OF-GERMANY [J].
DIEHL, V ;
PFREUNDSCHUH, M ;
LOFFLER, M ;
RUHL, U ;
HILLER, E ;
GERHARTZ, H ;
KIRCHNER, H .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1990, 116 (01) :106-108
[10]  
DIEHL V, UNPUB GHSG HD8 TRIAL